Lotus Pharmaceuticals, Inc.
Σύμβολο: LTUS
PNK
0.00401
USDΤιμή αγοράς σήμερα
-651.6106
Λόγος P/E
-3.8330
Δείκτης PEG
0.11M
MRK Cap
- 0.00%
DIV Απόδοση
Lotus Pharmaceuticals, Inc. (LTUS) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 2.7 | 2.7 | 2.9 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -32.8 | -32.8 | -32.8 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -2.7 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 30 | 32.7 | 29.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.net-debt | 0 | 0.1 | 0.1 | 0.1 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 0 | 0 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | 0 | 0 | 0 | 0 |
Συχνές ερωτήσεις
Ποιο είναι το Lotus Pharmaceuticals, Inc. (LTUS) το σύνολο του ενεργητικού?
Lotus Pharmaceuticals, Inc. (LTUS) το συνολικό ενεργητικό είναι 5681.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι N/A.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.000.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι -0.000.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι 0.000.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι 0.000.
Ποια είναι η Lotus Pharmaceuticals, Inc. (LTUS) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι -18812.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 116683.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 18812.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι 0.000.